Year: 2023

Uvax_Logo

Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia

NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and...